Powerful Medical Receives €40 Million IPCEI Grant — read the full story

Powerful Medical
17. July 2023

Pioneering the Future of Cardiology – PMcardio Joins Forces with Cardiovascular Research Center Aalst in an AI-Driven R&D Partnership

PRESS RELEASE: PMcardio, a market leader in AI-powered cardiovascular diagnostics, is thrilled to announce a research and development partnership with the Cardiovascular Research Center Aalst, a world-renowned authority in cardiology. The transformative alliance blends PMcardio’s state-of-the-art technology with the globally acclaimed clinical expertise of the Heart Center Aalst, aspiring to unlock new dimensions in cardiac care and improve patient outcomes.

“Bridging the gap between medical technology and patient care, this collaboration emphasizes the game-changing role of AI in healthcare and its ability to revolutionize the diagnosis and management of cardiovascular diseases,” says Martin Herman, CEO of Powerful Medical, the deep-tech firm behind PMcardio.

The partnership represents a strategic step towards accelerating advancements in cardiac care. By harnessing the potential of AI technology, this alliance aims to facilitate rapid research improvements, enabling early disease detection and timely treatment, thereby redefining the current standards of heart care.

Dr. Jozef Bartunek, Co-director of the Cardiovascular Center Aalst, expresses his enthusiasm, “Our R&D partnership with PMcardio aligns perfectly with our continuous efforts to remain at the forefront of cardiovascular innovation and advancing standards of care. We are eager to combine our extensive clinical expertise in advancing PMcardio’s progressive AI technology developed on clinically validated data sets, which has shown exceptional potential in ECG diagnostics.”

The AI-powered clinical assistant, PMcardio, allows healthcare professionals to diagnose 38 cardiovascular diseases with cardiologist-level precision in under 5 seconds. This collaboration aspires to enhance this capacity, further empowering medical professionals to deliver swift, accurate, and personalised patient care.

“Our partnership with the Cardiovascular Research Center Aalst enables us to venture deeper into the pioneering territory of healthcare innovation and provides us with access to their extensive clinical research network,” explains Dr. Robert Herman, Chief Medical Officer at Powerful Medical. “Together, we aim to expand the AI-powered diagnostic ECG capabilities in early detection of Heart Failure, Acute Coronary Syndrome (ACS), and a host of predictive diagnostics, thereby ushering a new era of cardiac diagnostics and patient care.”

About Cardiovascular Research Center Aalst:

The Cardiovascular Research Center Aalst, a top-tier tertiary, non-university center in cardiology, provides innovative and comprehensive care for patients with cardiovascular disease. With a commitment to maintaining the highest standards of patient care, their work continues to make significant contributions to the field of cardiology worldwide.

Pioneering the Future of Cardiology - PMcardio Joins Forces with Cardiovascular Research Center Aalst in an AI-Driven R&D Partnership
Pioneering the Future of Cardiology - PMcardio Joins Forces with Cardiovascular Research Center Aalst in an AI-Driven R&D Partnership

Stay on the pulse with our newsletter

Your submission was successful

Powerful Medical

Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
Powerful Medical leads one of the most important shifts in modern medicine by augmenting human-made clinical decisions with artificial intelligence. Our primary focus is on cardiovascular diseases, the world’s leading cause of death.
About PMcardio:

PMcardio is a CE-certified AI that reads ECGs and offers a complex assessment of 49 cardiac conditions. Clinically validated in 15+ studies and trusted by over 100,000 clinicians, it delivers rapid, expert‑level interpretations, empowering emergency physicians, GPs, nurses, paramedics, and cardiologists to act with confidence at the point of care. Available for Individuals and Organizations.

About Powerful Medical:

Established in 2017, Powerful Medical has embarked on a mission to revolutionize the diagnosis and treatment of cardiovascular diseases. We are a medical company backed by 28 world-class cardiologists and led by our expert Scientific Board with decades of experience in daily patient care, clinical research, and medical devices. The results of our research are implemented, developed, certified, and brought to market by our 50+ strong interdisciplinary team of physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial teams.

Share this article

Don't miss these

Powerful Medical awarded €40M IPCEI grant to expand AI diagnostics for heart attacks, heart failure, and arrhythmias

Powerful Medical Receives €40 Million Non-Dilutive Grant to Accelerate Early Diagnosis of Cardiovascular Diseases with AI

Powerful Medical announces it has been selected to receive over €40 million in non-dilutive funding from the European Commission’s IPCEI Tech4Cure initiative. This significant grant will accelerate global adoption and clinical validation of PMcardio®, the world’s first AI-powered platform enabling rapid and accurate diagnosis of heart attacks and other life-threatening cardiac conditions, dramatically expanding the company’s potential to save millions of lives worldwide.
Image is showing logos of the two companies mentioned in the text - PMcardio and Alphaiota

Alphaiota Expands Strategic Partnership with PMcardio to Launch First AI-Powered Heart Attack Diagnostic Platform in Saudi Arabia

Alphaiota and PMcardio announce the expansion of their strategic partnership to bring the first AI-powered heart attack diagnostic solution to the Kingdom of Saudi Arabia. Developed by Powerful Medical, a medical device manufacturer specializing in AI-driven cardiovascular diagnostics, PMcardio will be introduced by Alphaiota as the exclusive distributor in the region, marking a first-of-its-kind deployment in the Middle East.

Join over 100,000 healthcare professionals who are already taking advantage of AI